Private and Public Investments in Biomedical Research
AEA Papers and Proceedings
vol. 111,
May 2021
(pp. 341-45)
Abstract
Recent policy attention has focused on proposals to reduce prices for drugs that have received public funding. From an implementation perspective, such policies rely on public disclosure of government support for research. In this paper, we highlight two conceptual problems with past attempts to measure these public disclosures and construct a new dataset that corrects for these problems. Our corrected measures suggest that underreporting of public research support is less of an issue than previously thought.Citation
Durvasula, Maya, Lisa Larrimore Ouellette, and Heidi Williams. 2021. "Private and Public Investments in Biomedical Research." AEA Papers and Proceedings, 111: 341-45. DOI: 10.1257/pandp.20211105Additional Materials
JEL Classification
- L65 Chemicals; Plastics; Rubber; Drugs; Biotechnology
- O32 Management of Technological Innovation and R&D
- H51 National Government Expenditures and Health
- I11 Analysis of Health Care Markets
- I18 Health: Government Policy; Regulation; Public Health